Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cardio Diagnostics Holdings (CDIO) Fair Value & Analysis

Healthcare · US · Market cap $5.9M

Price$2.03
Fair Value$1.73
Upside-14.8%
Quality95/100
Evidence: Low Range $1.14 – $2.17

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Cardio Diagnostics Holdings (CDIO) currently trades at $2.03, while our model-based Fair Value estimate is $1.73 — implying the stock looks roughly 14.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; a…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Cardio Diagnostics Holdings (CDIO) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.73 versus a price of $2.03 — about −15% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CDIO?
Our 21-model fair value for Cardio Diagnostics Holdings is $1.73 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.03.
What is the quality score of CDIO?
Cardio Diagnostics Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.